Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05206695
Other study ID # R61HL157804
Secondary ID R61HL157804
Status Recruiting
Phase N/A
First received
Last updated
Start date May 13, 2022
Est. completion date June 30, 2026

Study information

Verified date October 2023
Source University of California, San Francisco
Contact Sunitha V Kaiser, MD, MSc
Phone 415-476-3392
Email sunitha.kaiser@ucsf.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study's objective is to identify and test pragmatic and sustainable strategies for implementing a multi-condition clinical pathway intervention for children hospitalized with asthma, pneumonia, or bronchiolitis in community hospitals. The hypothesis is that the multi-condition pathway intervention will be associated with significantly greater increases in clinicians' adoption of evidence-based practices compared to control. The study is a pragmatic, cluster-randomized trial in US community hospitals. The primary outcome will be adoption of evidence-based practices over a sustained period of 2 years. Secondary outcomes include length of hospital stay, intensive care unit transfer, and hospital readmission/emergency department revisit.


Description:

Asthma, pneumonia, and bronchiolitis are the top causes of childhood hospitalization in the US, leading to approximately 350,000 hospitalizations and $2 billion in costs annually. Poor guideline adoption by clinicians contributes to poor health outcomes for children hospitalized with these respiratory illnesses, including longer recovery time/hospital stay, higher rates of transfer to intensive care units, and increased risk of hospital readmission. Pathways can improve clinicians' adoption of evidence-based practices/guidelines in both children's and community hospital settings. Pathways are simple, visual diagrams that guide clinicians step-by-step through the evidence-based care of a specific medical condition (accessed via paper or electronically). Most hospitals implement pathways for a single medical condition at a time (e.g., asthma). But Seattle Children's Hospital developed an intervention for simultaneously implementing pathways for multiple conditions. This intervention led to sustained guideline adoption, decreased length of stay, and decreased costs; and, these effects were comparable to those shown with single-condition pathway implementation. This multi-condition pathway intervention has not yet been studied in community hospitals, which face unique implementation barriers. The study's objective is to identify and test pragmatic and sustainable strategies for implementing a multi-condition pathway intervention for children hospitalized with asthma, pneumonia, or bronchiolitis in community hospitals. The study is a pragmatic, cluster-randomized trial in US community hospitals. The pathway intervention will be implemented using the key implementation strategies defined for this intervention (audit and feedback, electronic health record integration, plan-do-study-act cycles). The primary outcome will be adoption of evidence-based practices over a sustained period of 2 years. Secondary outcomes include length of hospital stay, intensive care unit transfer, and hospital readmission/emergency department revisit.


Recruitment information / eligibility

Status Recruiting
Enrollment 16800
Est. completion date June 30, 2026
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria: - Primary diagnosis of asthma AND age >2 to <18 years-old at time of admission to the hospital OR - Primary diagnosis of pneumonia AND age >2 months and <18 years at time of admission to the hospital OR - Primary diagnosis of bronchiolitis AND age <2 years at time of admission to the hospital Exclusion Criteria: - Diagnosis of SARS-CoV-2 - Transfer in from another inpatient facility - Pre-existing chronic illnesses (e.g., lung disease, cardiovascular disease, neurologic disorders)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Multi-condition Pathway Intervention
See Experimental/Arm 1 description

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
University of California, San Francisco National Heart, Lung, and Blood Institute (NHLBI), Society of Hospital Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pneumonia Evidence Based Practice 1 Administration of narrow spectrum antibiotic During a hospitalization, approximately 2 days
Primary Pneumonia Evidence Based Practice 2 No prescription of macrolide antibiotics During a hospitalization, approximately 2 days
Primary Asthma Evidence Based Practice 1 Prescription of inhaled corticosteroids for children greater than or equal to 5 years-old During a hospitalization, approximately 2 days
Primary Asthma Evidence Based Practice 2 Use of metered-dose inhalers During a hospitalization, approximately 2 days
Primary Asthma Evidence Based Practice 3 Use of an asthma pathway/bronchodilator weaning protocol During a hospitalization, approximately 2 days
Primary Bronchiolitis Evidence Based Practice 1 No administration of bronchodilators During a hospitalization, approximately 2 days
Primary Bronchiolitis Evidence Based Practice 2 No chest radiographs During a hospitalization, approximately 2 days
Secondary Length of Hospital Stay Length Hospital Stay During a hospitalization, approximately 2 days
Secondary Transfer to Intensive Care The event of patient being transferred to an ICU During a hospitalization, approximately 2 days
Secondary 30-day Hospital Readmission or Emergency Department Revisit Event of a patient being readmitted to hospital or having an emergency department visit within 30 days of hospital discharge 30 days after hospital discharge
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device